On September 12, 2025, Biocon Limited, a global biopharmaceutical company from India, announced the inauguration of its first US manufacturing facility in Cranbury, New Jersey. The facility, acquired from Eywa Pharma Inc. in 2023, has undergone a $30 million investment to become a state-of-the-art plant with an annual production capacity of 2 billion tablets. This strategic move enables Biocon to diversify its manufacturing base, strengthen its supply chain, and expand its global footprint.
The Cranbury facility will play a crucial role in Biocon’s US operations, providing faster access to essential therapies, enhanced supply reliability, and a stronger connection with partners and healthcare providers. According to Abhijit Zutshi, Chief Commercial Officer of Biocon Limited, the company’s decision to expand in the US is based on its strategy to create access to life-saving drugs, particularly in light of the COVID-19 pandemic.
The inauguration ceremony was attended by Governor Phil Murphy, who served as the guest of honor, along with Biocon’s Chairperson, Kiran Mazumdar-Shaw, and other dignitaries. Mazumdar-Shaw emphasized that the facility marks a new chapter in Biocon’s journey of global expansion and reaffirms the company’s purpose to serve patients worldwide. Governor Murphy praised Biocon’s decision to open its first US manufacturing facility in New Jersey, highlighting the state’s reputation as a hub for the pharmaceutical industry.
The Cranbury facility currently employs approximately 60 people, with plans to grow to around 80-85 employees in the next few months. Biocon’s CEO, Siddharth Mittal, expressed his gratitude to Governor Murphy and Mazumdar-Shaw for attending the inauguration, stating that the facility brings the company closer to patients, healthcare providers, and partners in the US market. The proximity of the facility will enable Biocon to deliver high-quality medicines more efficiently, ensuring supply chain resilience and advancing its mission to expand access to affordable therapies worldwide.
The establishment of Biocon’s first US manufacturing facility in New Jersey is a significant milestone for the company, marking its commitment to fostering innovation, creating job opportunities, and strengthening the US healthcare ecosystem. With its strategic location and state-of-the-art infrastructure, the facility is poised to play a vital role in Biocon’s global expansion and its mission to provide high-quality medicines to patients across the globe.